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Abstract: Membrane-integral pyrophosphatases (mPPases) are found in several human pathogens, 
including Plasmodium species, the protozoan parasites that cause malaria. These enzymes hydrolyze 
pyrophosphate and couple this to the pumping of ions (H+ and/or Na+) across a membrane to 
generate an electrochemical gradient. mPPases play an important role in stress tolerance in plants, 
protozoan parasites, and bacteria. The solved structures of mPPases from Vigna radiata and 
Thermotoga maritima open the possibility of using structure-based drug design to generate novel 
molecules or repurpose known molecules against this enzyme. Here, we review the current state of 
knowledge regarding mPPases, focusing on their structure, the proposed mechanism of action, and 
their role in human pathogens. We also summarize different methodologies in structure-based drug 
design and propose an example region on the mPPase structure that can be exploited by these 
structure-based methods for drug targeting. Since mPPases are not found in animals and humans, this 
enzyme is a promising potential drug target against livestock and human pathogens. 
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Abbreviations: 
PPi: inorganic pyrophosphate; 
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Pi: inorganic phosphate; 
PPase: pyrophosphatase; 
sPPase: soluble pyrophosphatase; 
mPPase: membrane-bound pyrophosphatase; 
IPTG: β-D-1-thiogalactoside; 
TMH: transmembrane helix; 
Na+-mPPase: Na+-pumping membrane-bound pyrophosphatase; 
Na+/H+-mPPase: Na+ and H+-pumping membrane-bound pyrophosphatase; 
V-ATPase: vacuolar ATPase; 
AVP1: H+-mPPase in Arabidopsis; 
DALYs: disability adjusted life years; 
FDA: US Food and Drug Administration; 
FPPS: farnesyl diphosphate synthase; 
SI: selectivity indexes; 
CC50: 50% cytotoxicity concentration; 
EC50: 50% effective concentration; 
VrPPase: Vigna radiata membrane-bound pyrophosphatase; 
IDP: imidodiphosphate; 
TmPPase: Thermotoga maritima membrane-bound pyrophosphatase; 
RMSD: root mean square deviation; 
GPCR: G protein-coupled receptors; 
ADME: absorption; distribution; metabolism and excretion; 
PAMPA: parallel artificial membrane permeability assay; 
CYP: cytochrome P450; 
hERG: human ether-à-go-go-related gene; 
P-gp: permeability glycoprotein; 
ABCC2: ATP-binding cassette sub-family C member 2; 
MATE: multi-antimicrobial extrusion protein; 
NMR: nuclear magnetic resonance; 
SPR: surface plasmon resonance; 
HTS: high throughput screening; 
DUD: directory of useful decoys 
MCSS: multiple copy simultaneous search; 
dCTPase: deoxycytidine triphosphate pyrophosphatase 1; 
IPP: isopentenyl diphosphate 
dNTPs: nucleotide triphosphates; 
AMDP: aminomethylenediphosphonate. 
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1. Introduction 
Inorganic pyrophosphatases catalyse the hydrolysis of inorganic pyrophosphate (PPi) to two 
inorganic phosphate (Pi) molecules. PPi is a by-product of at least 190 cellular reactions, including 
the generation of the fundamental building blocks of life: polynucleotide chain synthesis and 
generation of aminoacyl-tRNA. Controlling the level of PPi is crucial for driving these reactions 
forward, thus highlighting the importance of pyrophosphatases (PPases) [1–4]. PPi also plays a 
regulatory role in the cell as an intracellular biochemical intermediate of several enzymes and e.g. in 
mammals as an inhibitor of calcification in connective tissue matrices and other extracellular  
fluids [2,5]. 
Managing the level of PPi in the cell through PPi hydrolysis is primarily accomplished by the 
ubiquitous soluble PPases (sPPases), which have kcat ranging from 200 to 2000 s-1, as opposed to the 
much slower membrane-bound PPases (mPPases) with kcat  of approximately 10 s-1 [2,6]. Chen et al. 
demonstrated that sPPase is essential in Escherichia coli through replacement of the chromosomal 
copy of ppa, the sPPase gene, with ppa under the control of a lac promoter. This strain grew in the 
presence of isopropyl β-D-1-thiogalactoside (IPTG), which induced expression of sPPase, but was 
unable to grow in the absence of IPTG [7]. Mitochondrial sPPase in Saccharomyces cerevisiae is 
also essential for cell viability, since this enzyme is required for mitochondrial function [8]. E. coli 
sPPase, and other bacterial sPPases, are homohexamers whereas the S. cerevisiae sPPase is a 
homodimer, though the monomeric fold of these various proteins is the same [9,10]. 
Unlike the globular sPPase, mPPase is embedded in the membrane via 15 to 17 transmembrane 
helices (TMHs), with no globular domain [11,12]. In addition to hydrolyzing PPi, mPPases couple 
this action with the pumping of ions across the membrane to generate an electrochemical gradient 
[13]. This ion gradient can be utilized as a source of energy by the cell during times of stress [14]. 
Also unlike the sPPases, mPPases only occur in algae, plants, selected species of protozoan parasites, 
bacteria and archaea – but not in animals or fungi [13,15,16]. Below, we discuss the biology, 
function and structure of mPPases, and finish by discussing the possibility of using mPPases as a 
novel drug target. 
2. mPPase Sub-Families 
mPPase enzymes are divided into four groups based on their requirement for K+, and the ion or 
ions that they pump across the membrane (summarized in Table 1). The first group consists of 
mPPases that translocate H+ across the membrane in a K+-independent manner [17]. Second, are 
mPPases that pump H+ across the membrane, but require 30 to 50 mM K+ for optimal activity [18]. 
Dependence on K+ for function is due to the presence or absence of a key lysine residue in the active 
site; in K+-independent mPPases the lysine side chain functionally replaces the K+ ion. This was 
demonstrated with the K+-dependent, H+-pumping mPPase from Carboxydotherums 
hydrogenoformans: this enzyme was converted to a K+-independent mPPase when the alanine 460 
residue, which is at the position of the conserved lysine in K+-independent mPPases, was mutated to 
lysine [19]. The structural basis is not yet certain, as there are no structures of a K+-independent 
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mPPase, but modeling suggests that it is a direct structural replacement of the K+ by the lysine 
sidechain [11]. 
Table 1. mPPase protein subfamilies. 
Subfamily K+ requirement Example organisms 
H+-pumping, K+-independent No Streptomyces coelicolor, Plasmodium falciparum 
VP2 
H+-pumping, K+-dependent Yes Plasmodium falciparum VP1, Trypanosoma 
cruzii, Vigna radiata* 
Na+-pumping Yes Thermotoga maritima*, Clostridium tetani 
Na+ and H+-pumping Yes Bacteroides vulgatus 
*The structure has been solved for the protein from these organisms [11,12]. 
The remaining two mPPase groups are K+-dependent: Na+-pumping mPPases (Na+-mPPases) 
and finally, dual-pumping mPPases that translocate both Na+ and H+ (Na+/H+-mPPases) [13,20]. 
Phylogenetic analysis suggests Na+-mPPases are the ancestral proteins with H+-pumping having 
evolved via four separate evolutionary lineages [20,21]. Dual Na+/H+-mPPases likely evolved from 
Na+-pumping proteins via the acquisition of key mutations that are conserved in the subfamily, i.e. 
Bacteroides vulgatus residues Thr90 (which can also be a serine in other species), Phe94, Asp146, 
and Met176 [13,22]. 
3. Biological Roles of mPPases 
Though sPPases are primarily responsible for regulating intracellular PPi levels, the ability of 
mPPases to translocate H+ and/or Na+ across a membrane against a concentration gradient enables it 
to play a variety of roles in different organisms. Dual-pumping Na+/H+-mPPases are found only in 
bacteria and Na+-mPPases are found in both bacteria and archaea. H+-pumping mPPases are the most 
widely distributed, being present in all three domains of life [19–21]. 
3.1. Plants 
H+-pumping mPPases are present in all members of the green line of evolution where the 
chloroplast was gained, which includes algae and land plants [15,23,24]. These enzymes couple 
cleavage of PPi with pumping of H+ across the vacuolar membrane, and together with the vacuolar 
ATPase (V-ATPase), acidify the vacuole, which is critical for maintaining its multiple functions, 
including solute and protein storage [17,25–29]. mPPases in plants play important roles in 
development and stress-resistance [30,31]. Overexpression of the mPPase AVP1 in Arabidopsis 
results in augmented root growth and larger leaf size and AVP1 loss of function leads to stunted 
growth and development [30]. Overexpression of mPPase in various species of plants also improves 
resistance to drought and salt-stress [32–35]. It is thus possible to develop stress-tolerant crops 
through overexpressing or manipulating mPPases, which could help offset the declines in 
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agricultural productivity and worldwide food security [36] that are expected, as global warming 
increases the incidence of drought [37]. 
3.2. Protozoan parasites 
Protozoan parasites are unicellular eukaryotes that are responsible for numerous human diseases, 
including malaria (caused by Plasmodium spp.), toxoplasmosis (caused by Toxoplasma gondii), 
trypanosomiasis (caused by Trypanosoma spp.) and leishmaniasis (caused by Leishmania spp.) [38]. 
Plasmodium spp. and T. gondii are protozoan parasites from phylum apicomplexa, whereas 
Trypanosoma spp. and Leishmania spp. are from class kinetoplastida. Apicomplexans and 
kinetoplastids differ in two ways. Apicomplexan parasites have a unique organelle called the 
apicoplast at their cell tip that is essential for penetrating the host cell, and, even though they do not 
have flagella or cilia, most apicomplexan cells are motile, as they utilize a gliding mechanism [39]. 
In contrast, kinetoplastids have a single flagellum at the posterior end of their cell for motility and a 
kinetoplast, located near the basal body of the flagellum, which is a mitochondrial genome consisting 
of thousands of molecules of topologically interlocked circular DNA. Both apicomplexans and 
kinetoplastids have H+-pumping mPPases, not found in humans, that are important for their survival 
during their life cycle (discussed below). 
Malaria, toxoplasmosis, and leishmaniasis have disability adjusted life years (DALYs) in the 
millions with far-reaching global distributions [40]. African trypanosomiasis (Trypanosoma spp.) is 
similar: it blights the lives of ~60 million people in sub-Saharan Africa with ~0.6 million DALYs in 
2010 [40]. Of these, malaria has the greatest worldwide impact, with the World Health Organization 
estimating 198 million cases and 584 000 deaths due to malaria in 2013 alone [41]. For the purpose 
of this review, we will use malaria as the prime example to illustrate the various transitions that 
occur throughout the protozoan parasite life cycle, though similar transitions occur in the other 
parasite species as well. Malaria is caused by several Plasmodium species, with Plasmodium 
falciparum being the most prevalent and virulent, and these unicellular parasites are transmitted 
between humans by Anopheles mosquito vectors [41,42]. To date, there are no effective, FDA-
approved vaccines against malaria, presumably due to the complexities of malarial immune 
resistance [43]. Despite repeated exposure, most individuals living in areas where malaria is endemic 
are not immune to Plasmodium infection, though they appear asymptomatic and therefore remain 
untreated [43,44]. This population of individuals thus acts as a reservoir for the malaria parasite. 
Fighting malaria is further complicated by the emergence of P. falciparum strains, especially in 
south-east Asia [45], that are resistant to most of the currently-available drugs. The key to tackling 
the global malaria problem may lie in exploiting the transition between key stages of the complex 
life cycle of this host-dependent parasite. 
The Plasmodium parasite has three major life cycle stages: the human liver stage, the human 
blood stage, and the mosquito stage [42,43]. The human liver stage begins when a female 
Plasmodium-infected Anopheles mosquito transfers the elongated and motile form of the parasite, the 
sporozoite, from the saliva into the human dermis while it feeds on human blood. These sporozoite 
parasites reach the bloodstream and travel to the liver, where they invade hepatocytes and  
replicate [46,47]. Inside the hepatocytes, the sporozoites differentiate into merozoites, an asexual 
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form of the parasite, which are released into the bloodstream, thereby beginning the human blood 
stage [47,48]. The merozoites, which are the main pathogenic form, then go on to infect erythrocytes, 
in which they replicate and produce more merozoite cells that are again released into the bloodstream. 
During the human blood stage, some merozoites also differentiate into male or female gametocytes, 
the non-pathogenic, sexual form of the parasite. The mosquito stage of the life cycle is initiated when 
mosquitoes take up the gametocyte form of Plasmodium when they feed on infected human blood. In 
the mosquito, the gametocytes combine in the midgut and produce new, asexual sporozoites, which 
replicate and spread to the salivary glands, where the parasitic cells can begin the cycle again when 
the infected mosquito feeds on and infects another human [42,43]. 
During the parasitic life cycle, the unicellular protozoan cell experiences transitions between 
environments with different levels of osmotic pressure, from intracellular to extracellular 
environments and from human to vector host environments. Even within the vector insect gut alone, 
the osmolarity can vary from 320 to 1000 mosmol/kg, depending on the feeding activities of the 
insect [49]. To survive the changes in environment, the parasites must quickly adjust their internal 
osmotic pressure [50]. One major mechanism for dealing with this osmotic stress involves a small 
organelle known as the acidocalcisome [51]. The acidocalcisome acts as an acidic storage 
compartment for numerous ions, including Ca2+, polyphosphate and PPi [52–55]. During osmotic 
stress, parasites are able to rapidly hydrolyze or synthesize polyphosphate to adapt to different 
osmotic environments and to release the energy stored in the polyphosphate molecule [56]. 
Polyphosphate chelates Ca2+ ions, and therefore the acidocalcisome likely plays a role in regulating 
Ca2+ levels in the protozoan cell [57]. Maintaining a low pH within the acidocalcisome is crucial for 
acidocalcisome function, and loss of acidocalcisome acidity leads to a 10 fold decrease in 
polyphosphate levels in the acidocalcisome, a loss of intracellular pH regulation, and decreased 
growth rate and final cell density in the protozoan parasite Trypanosoma brucei (the cause of African 
sleeping sickness) [58]. A high concentration of H+ within the acidocalcisome is also important for 
regulating Ca2+ levels, since one mechanism of Ca2+ uptake into the acidocalcisome is the exchange 
of H+ for Ca2+ by Ca2+-ATPase [59]. Fusion of the acidocalcisome with the contractile vacuole 
complex and translocation of aquaporin, which is a water channel, to the contractile vacuole also 
plays a significant role in osmoregulation in protozoans. This cyclic-AMP- and microtubule-
dependent fusion mediates the regulatory volume decrease process in Trypanosoma cruzi under 
hypo-osmotic stress conditions [60]. 
3.3. Are mPPases validated drug targets? 
Just as in plant vacuoles, there are two types of proton pumps in protozoan acidocalcisomes: 
H+-ATPases and H+-pumping mPPases [61–63]. Knocking down H+-pumping mPPase expression in 
T. brucei prevents acidocalcisome acidification, causes a 90% reduction in polyphosphate, and 
prevents stabilization of intracellular pH on exposure to external basic pH; thus, H+-ATPase activity 
alone is not sufficient for acidocalcisome activity and a normal parasite [58]. In T. gondii, knockout 
mutants of mPPase display a reduction in the virulence of tachyzoites in mice; these are the fast-
growing, asexual form of the parasite [64]. In addition, Rodrigues et al. showed that bisphosphonate 
derivatives (mPPase inhibitors) were able to significantly inhibit intracellular proliferation of T. 
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gondii in human foreskin fibroblasts without affecting the host cells [65]. Bisphosphonate derivatives 
also inhibit the growth of P. falciparum, T. brucei, T. cruzi, and Leishmania donovani with 
nanomolar or low-micromolar IC50 values [65–67]. However the mechanism of action of these 
bisphosphonates is complex, as they inhibit not only mPPase, but also farnesyl pyrophosphate 
synthase (FPPS), which occurs in mammalian cells as well [67]. Indeed, bisphosphonates are used to 
treat bone diseases [68]. Despite the fact that bisphosphonates are used to inhibit human enzymes, a 
recent study by Yang et al. suggests several lipophilic bisphosphonate molecules have the potential 
to be used against T. brucei in humans without harmful side effects [39,69,70]. Bisphosphonate 
compounds were screened for cytotoxicity in HEK293T cells and several of these molecules 
exhibited selectivity indexes (SI) (HEK293T cell 50% cytotoxicity concentration (CC50)/50% 
effective concentration (EC50) against T. brucei) of greater than 50 [39]. Therefore, though most 
bisphosphonate compounds are not potential candidates as anti-parasitic drugs due to cytotoxicity 
against human cells, modification of these compounds could lead to decreased cytotoxicity while 
inhibiting parasitic enzymes. 
Together, these studies highlight the importance of PPi-driven proton transport by mPPases in 
protozoan parasites. They clearly indicate mPPases are viable potential drug targets against human 
protozoan parasites. By targeting the protozoan mPPase and thus interfering with pH regulation and 
the ability to adapt to varying osmolarity, protozoan pathogens may no longer survive the transition 
to different host environments. 
3.4. mPPases in bacterial pathogens 
mPPases are only present in select bacterial species; even within a single genus, some species 
have an mPPase gene whereas others do not. This is exemplified by the genus Clostridium, in which 
several species, such as Clostridium leptum and Clostridium botulinum, have Na+/H+ mPPases 
whereas other species, such as Clostridium difficile and Clostridium perfringens, lack mPPase genes 
entirely [13,21] (Shah, N. R. and Goldman, A. unpublished data). Bacterial species that possess 
mPPases that are of great importance to human health are B. vulgatus and Bacteroides fragilis, along 
with several other members of genus Bacteroides [13]. In healthy individuals, Bacteroides form a 
mutualistic relationship with the human host as part of the intestinal microbiota [71–74]. However, 
when these bacteria escape the gut environment, they can cause bacteraemia and abscesses in various 
places in the human body, including the brain [75–77]. Bacteroides are the most commonly isolated 
anaerobic pathogen in humans, and bacteremia caused by Bacteroides species has an associated 
mortality rate of over 19% [77,78]. Moreover, they have the highest resistance rates of all anaerobic 
pathogens, likely due to a wide variety of antibiotic resistance mechanisms [77,79,80], meaning that 
novel, Bacteroides-specific drugs would be of great use. 
B. vulgatus has a dual-pumping Na+/H+-mPPase embedded in the inner membrane that 
hydrolyzes PPi at the cytoplasmic face of the membrane and pumps ions across the inner membrane 
to the periplasm against a concentration gradient [13]. As in plants, overexpression of mPPase in 
bacteria leads to greater resistance to stressors, including heat, hydrogen peroxide, and high 
concentrations of NaCl [81]. Though mPPases are not essential for bacterial survival, inhibiting this 
enzyme will likely diminish the viability of Bacteroides cells, especially under stressful conditions. 
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Furthermore, in principle a molecule that could force the mPPase ion gate open, rather than just 
inhibiting the enzyme, would lead to a leaky inner membrane, collapse the electrochemical gradient 
driving ATP synthesis, and so cause bacterial cell death. Specifically targeting the mPPase in B. 
vulgatus would have the added bonus of only affecting bacteria that possess mPPases, thereby 
limiting disturbance of the gut flora, which can lead to antibiotic-associated diarrhea in 15-25% of 
antibiotic-treated patients. Colonization of the gut by the microbiota also plays a role in protection 
against pathogens, so targeting just a fraction of the microbiota could be beneficial [82]. For instance, 
a significant risk of antibiotic treatment is overgrowth of C. difficile that can lead to recurring C. 
difficile-induced colitis [83]. Targeting mPPase-containing organisms may not carry the same risk, as 
much of the microbiota would be preserved [84]. 
4. Structure and Function of mPPases 
4.1. Overall structure of mPPases 
Until now, only the mPPase structure from two species have been solved – one from mung bean 
(VrPPase) in the inhibitor (imidodiphosphate, IDP) bound state (VrPPase:IDP:Mg5) [12] and one 
from T. maritima (TmPPase) in the resting (TmPPase:Ca:Mg) and product bound states 
(TmPPase:Pi2:Mg4) [11]. VrPPase is a proton translocating enzyme and TmPPase is a sodium-
translocating enzyme. Both structures were solved by X-ray crystallography. The overall structures 
of both enzymes are very similar (Cα’s root mean square deviation (RMSD) 1.57 Å), with complete 
conservation of the position and identity of all catalytic residues [6]. Both structures consist of a two-
fold symmetric homodimer in which each monomer has 16 TMHs (Figure 1A) [11,12]. In the 
TmPPase structure, the dimeric interface is mainly formed via hydrophobic interaction of TMH10, 
13, and 15 and some hydrogen bonds [11] as well as an ion pair formed by the C-terminal 
carboxylate. In VrPPase, in addition to hydrophobic interactions and hydrogen bonds, the dimeric 
interface contains two salt bridges [12]. 
The TMHs of each monomer forms a rose-like arrangement consisting of two rings of helices 
(Figure 1B). The inner ring consists of six TMHs (TMH5-6, TMH11-12, and TMH15-16) and the 
outer ring consists of the other ten (TMH1-4, TMH7-10, and TMH13-14). Viewed from the 
cytoplasmic side, both rings are arranged sequentially counterclockwise with the exception of  
TMH1 [12]. However, the helices in the two rings have opposite tilts (Fig 1B), such that the inner 
ring of helices appears to be tilted “clockwise”, and the outer ring, except for TMH1, 
“counterclockwise”, viewed from the cytoplasm (Figure 1B).  Viewed parallel to the membrane (data 
not shown), this corresponds to the inner ring helices being tilted on average -20° (counterclockwise) 
from the vertical, and the outer ring helices, except for TMH1, being tilted on average +19° 
(clockwise). This crossing angle between the helices is thus about 40°, similar to a classic “ridges-in-
grooves” arrangement. 
TMHs of the inner ring form the active site for the hydrolytic reaction and ion pumping (Figure 
1C). The inner ring of helices is comprised of four distinct areas: (i) the hydrolytic center, (ii) the 
coupling funnel, (iii) the gates below the membrane surface, and (iv) the exit channel [11]. The 
hydrolytic center, about 20 Å above the membrane surface, is a funnel-shaped pocket with highly 
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conserved residues consisting of 12 acidic residues (D5.61, D5.65, E5.76, D5.77, D6.35, D6.39, D6.43, D11.57, 
D15.61, D16.31, D16.35, D16.39), three basic residues (K5.58, K15.64, K16.38) and an asparagine  
(N12.53) [11,12] (Ballesteros-Weinstein residue numbering as described in Tsai et al. [22]). These 
residues are important for substrate binding either directly or indirectly via Mg2+ or water. The 
coupling funnel consists of an ionic network of eight conserved charged residues on TMH5-6, 
TMH11-12, and TMH16 (R5.50, K5.58, D6.39, D6.50, D11.50, K12.50, K16.38, D16.39) and mutation of any of 
these residues has major effects on function [85]. Below the coupling funnel lie the ionic and 
hydrophobic gates. The ionic gate is comprised of the conserved-charged, and hydrophilic residues 
in TMH 5, 6, and 16 (S5.43, D6.50, E6.53, S6.53, S6.54, D16.46, K16.50). The hydrophobic gate is located 
below the ionic gate, and is formed by semi-conserved non-polar residues from four TMHs of the 
inner barrel (TMH5, 6, 12, and 16). This gate likely has the essential function of preventing ion 
back-flow from the lumen/periplasm to the cytoplasm (6). Below the hydrophobic gate lies the exit 
channel, which facilitates ion release to the lumen/periplasmic region. Among mPPases, the residues 
in the exit channel are not conserved, which indicates this region does not play a significant role in 
the ion release mechanism. 
 
Figure 1. Structure of membrane bound pyrophosphatase. (A) The dimeric structure of 
TmPPase [11]. The different colors (green and pink) represent the two subunits. The blue 
and yellow spheres show the position of Mg2+ and Ca2+ ions in the hydrolytic center, 
respectively. (B) Inner (green) and outer (red) ring of TMHs drawn as cylindrical 
cartoons. Black circle represents helical folding sequence and grey circle represents the 
helical orientation. (C) Scheme of mPPase structure showing the hydrolytic center on the 
top (orange), the coupling funnel (pink), the gate (red), and the closed exit channel in the 
bottom (light blue). 
4.2. Hydrolysis and pumping mechanism 
Upon substrate binding, the most prominent conformational changes occur in TMH6, 11, and 
12 (Figure 2A). In the resting state structure of TmPPase, the funnel-shaped pocket is open to the 
cytoplasmic environment with a pocket volume of 2581 Å3 (Figure 2B, left panel). The conserved 
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loop 5-6 cannot be observed in this structure due to a lack of electron density, which is probably due 
to the flexibility of the loop. Upon substrate binding, the overall TMH structure in the cytoplasmic 
side constricts via TMH movement toward the center of the binding pocket (Figure 2A-B). This 
constriction leads to reduction of the pocket volume to 602 Å3 (1,521 Å3 [12]) based on the 
VrPPase:IDP:Mg5 structure (Figure 2B, middle panel). In this structure, loop 5-6 is clearly ordered 
(Figure 2A, arrowhead). It blocks the active site and E2685.75 binds the IDP indirectly via two water 
molecules [12]. The substrate is located and coordinated for enzymatic hydrolysis by five Mg2+ ions, 
one K+, and the side chains of seven residues (K2505.58, D2535.61, D69115.61, K69415.64, D72716.35, 
K73016.38, and D73116.39). The K+ ion increases the kcat over three-fold [86]. After hydrolysis and ion 
pumping has occurred, the capping of the funnel opens again, as seen in the TmPPase:Pi2:Mg4 
structure (Figure 2B, right panel). In this conformation, the helices are still constricted toward the 
center of the binding site and there is a further decrease of the pocket volume to 407 Å3. However in 
this structure, loop 5-6 is no longer observed, either due to conformational changes after hydrolysis 
that cause it to become flexible (to facilitate the pocket opening for phosphate release) or due to the 
low resolution of the structure (4.0 Å) [11]. 
 
Figure 2. Movement of transmembrane helices in mPPase upon substrate binding. (A) 
Superposition of TmPPase structure in resting state (pale yellow), VrPPase structure in 
inhibitor bound state (salmon), and TmPPase structure in product bound state (sky blue). 
All structures were drawn as cylindrical cartoons. The arrowhead points at the loop 5-6 
in the inhibitor bound state of VrPPase. (B) Cartoon representation of three mPPase 
structures showing the hydrolytic pocket (blue white) of each structure viewed parallel 
(upper panel) and perpendicular (lower panel) to the membrane. The molecular volume 
of each pocket was determined using the Splitpocket server 
(http://pocket.med.wayne.edu/patch/) [130,131]. 
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Though there are some conformational changes in the TMHs on the cytoplasmic side, the 
overall TMH conformation on the lumen/periplasmic side of the enzyme is quite rigid. In the 
structures of both mPPase species, the gate and exit channel are closed, so the exact mechanism of 
H+ or Na+ pumping is still not clear [11,12]. Based on the structure of VrPPase:IDP:Mg5, Lin et al. 
proposed a “Grotthuss-chain” mechanism to explain the proton translocation process from the 
cytoplasm to the vacuolar lumen. In this mechanism, the binding of PPi to the funnel-shaped pocket 
induces the nucleophilic attack of the water molecule, which interacts with D2876.39 and D7316.39 via 
hydrogen bonds, to one of the phosphate groups of PPi; this results in the breaking of the 
phosphoanhydride bond and produces two Pi and one H+ ion. The H+ ion is then translocated to the 
exit channel in the lumen through a Grotthuss-chain formed by a series of hydrogen bond-forming 
residues in the coupling funnel. 
Since TmPPase transports Na+ ion instead of H+, a Grotthuss-chain mechanism is not possible. 
Therefore, Kellosalo et al. proposed a “binding change” mechanism [11]. In comparing the different 
structures of TmPPase and VrPPase, there is a 2 Å downward motion of TMH12 upon closing of the 
funnel-shaped pocket due to substrate binding. The movement of TMH12 is facilitated by the 
presence of a conserved flat hydrophobic surface (A12.53, I12.54, A12.57, A/I12.58) in the vicinity of the 
coupling funnel, which acts as a lubricant [11]. This movement probably drives opening of the gate 
and exit channel [11,87]. Mutation of I545A12.54 and other residues in this region on VrPPase results 
in normal hydrolysis activity but a loss in H+-pumping, which means there is uncoupling between 
PPi hydrolysis and proton translocation [87]. Based on these data, Kellosalo et al. [11] proposed that 
PPi binding to the active site induces a larger-scale conformational change than that seen in the static 
structures. In addition to the closing of the loop between TMH5 and 6, TMH12 would move down 
further than the 2 Å observed (see above); opening the gate and the exit channel and resulting in the 
diffusion of an ion to the extracellular medium. This transport increases the overall negative charge 
in the active site due to loss of the Na+ (H+ in the proton pumping enzymes) and in particular 
increase the negative charge on residues D16.39 and D6.43 (the residues that bind the nucleophilic 
water molecule). This would lead to proton abstraction and catalysis. After hydrolysis, the 
electrophilic phosphate dissociates from the enzyme, followed by the leaving-group phosphate. This 
mechanism has the advantage over the “Grotthus-chain” mechanism because it can explain how H+-
pumping and Na+-pumping mPPases nonetheless have structurally-conserved active sites [11]. 
The importance of mPPase and the availability of structural data give this enzyme great 
practical interest for structure-based drug design methods to fight various human pathogens. 
5. Structure-Based Drug Design for mPPase 
Membrane proteins comprise about 25% of all proteins in the cell and more than 60% of them 
are drug targets [88,89]. Among drugs available in the DrugBank database [90] that target human 
membrane proteins, ~36% target G protein-coupled receptors (GPCRs) and ~8% target ligand-gated 
ion channels [89]. However, only a small fraction of drugs (~1%) in the database target parasitic 
organisms [89]. Therefore, since parasitic diseases have worldwide health, social, and economic 
impacts [40], new drugs targeting human parasites are urgently needed. 
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5.1. General requirements for drug discovery 
For a compound to be a potential drug candidate, there needs to be evidence that it has a 
disease-modifying action. It is thus clearly important whether the target has been validated or not: as 
discussed above, mPPases are validated targets, both by RNAi experiments [58] and because of the 
effect of bisphosphonates [65–67]. The further research on the effect of small molecules that is 
nonetheless required would benefit from chemical probes (see below). Another important step is to 
establish a proof-of-concept that potent mPPase inhibitors would have an effect ex vivo and in animal 
models. Promising lead compounds targeted at the mPPase can be, for example, further explored 
using P. falciparum and L. major in ex vivo and mouse models. 
A second critical aspect required for a clinical candidate molecule is to achieve a concentration-
time profile in the body that is adequate for the desired efficacy and safety. This is done by 
optimizing, via synthesis of analogues, the compound profile with respect to its absorption, 
distribution, metabolism and excretion (ADME) properties. The most common tests are compound 
permeability (membrane permeation assays such as Caco2 or parallel artificial membrane 
permeability assay (PAMPA)), solubility and plasma protein binding (which will be determinants in 
compound bioavailability, and therefore the dose taken; higher doses means higher probability of 
adverse effects), and metabolic profile (cytochrome P450 (CYP) inhibition). In the case of mPPases, 
compounds would be orally absorbed and the site of action would be the blood. A favorable ADME 
profile is usually sought during the early stages of the project when compound libraries are prepared, 
by avoiding compounds likely to have poor absorption or permeability. The first published and best-
known set of rules for design is Lipinski’s “rule of five”, meant to avoid poor absorption or 
permeability: no more than five hydrogen bond donors, no more than ten hydrogen bond acceptors, 
molecular mass less than 500 Da, and calculated Log P (lipophilicity of the compound) less than  
5 [91]. 
The third important aspect is toxicity and adverse effects. The commonly tested toxicities are 
cardiac toxicity (human ether-à-go-go-related gene (hERG) channel inhibition) as well as 
hepatotoxicity and liver injury; the latter is, in some cases, a consequence of drug-drug interactions 
at transporters (permeability glycoprotein (P-gp), but also ATP-binding cassette sub-family C 
member 2 (ABCC2) and multi-antimicrobial extrusion protein (MATE)) and metabolic enzymes 
such as CYPs. Promiscuous binding, which may lead to adverse effects, is further tested against 
panels of common targets (GPCRs, kinases). In addition, tests are usually conducted on counter-
targets, such as phylogenetically related proteins and proteins binding chemically similar ligands. 
For mPPases, mammals do not contain homologous proteins, making this enzyme a feasible target 
for drug design. Nonetheless, care should be taken because compounds targeted at phosphate sites 
are likely to bind promiscuously to other (pyro)phosphate binding proteins – such as FPPS (see 
above). The compounds developed should be designed to be specific by taking advantage of unique 
regions and aspects of the binding pocket. 
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5.2. Experimental screening 
At the moment only bisphosphonates are known to inhibit the mPPase. The first step to start in 
any drug development project is to discover novel hit compounds, and in order to do so, a robust 
assay is needed to complement the virtual screening (below). In our case we have at our disposal an 
assay to determine the orthophosphate released from the mPPase activity based on the molybdenum 
blue reaction [92], which we adapted for high throughput screening (Vidilaseris, K. unpublished). 
Hit discovery usually starts with a screening campaign. The libraries may be small to medium 
size to large size. A current trend in screening is towards miniaturization and automation of 
screening assays to reduce costs. An important factor is the druggability of the target, i.e. our ability 
to modulate it with small molecules [93,94]. In addition, the response towards several analogues is 
useful to see if trends in the structure-activity relationships may be discerned during screening. 
Fragment-based drug discovery has received a lot of attention since the seminal paper of Shuker 
and coworkers [95]. The strategy is built around assembling small fragments, whose binding is 
identified by nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), X-ray 
crystallography (soaking of fragment libraries into crystals), or by other biochemical methods. The 
crystallographic approaches require crystals that diffract to 2.5 Å or better, which is higher-
resolution than all except one of the mPPase structures. For GPCRs, another class of membrane 
proteins, fragment based discovery has proven useful [96] even if NMR screening has required 
working with protein that is thermostabilized, solubilized and attached to a resin [97]. Such a 
screening campaign can benefit from the use of computational methods, as described below. One 
obstacle to the use of such methods is that virtual screening methods need known inhibitors as a 
control; these do not currently exist for mPPases, as bisphosphonates are so unique they do not work 
well as a positive control in virtual screening. 
5.3. Computational screening 
Computational approaches have become ever more important in modern drug discovery [98]. In 
virtual screening, each molecule from a virtual chemical library is docked into the binding pocket 
and then evaluated by estimating the binding affinity and the fitness within the pocket. Then, the 
obtained score is used to rank the compounds and select the best hits for experimental testing and 
biological activity assays. This method can improve the hit rate since only the compounds that are 
most likely to bind are screened with in vitro assays. It is therefore quicker and cheaper than 
experimental high throughput screening (HTS) for producing promising binders [99], and provides a 
useful first step in an experimental high-throughput pipeline. There are several phases in virtual 
screening: (i) preparation of the target and database, (ii) docking, scoring, and validation, and (iii) 
ranking the compounds for experimental testing [99]. 
Docking-based virtual screening methods are used to rank libraries based on docking scores. 
Docking screening usually uses a flexible ligand-rigid protein approach. Decoy compounds are used 
as controls similar to known active compounds; these can be selected from the Directory of Useful 
Decoys (DUD) for example [100]. The controls are used to find the optimal parameters to retrieve 
known compounds with a high rank, better than the inactive decoys. To evaluate the best set of 
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possible solutions from a sampling process, a scoring function is applied. Algorithms commonly 
used for this purpose include force-field-based scoring functions (calculating the binding energy as 
the sum of non-bonded interactions between the ligand and the binding site) [101], empirical 
functions (breaking down the binding energy into several components, multiplying them by a certain 
coefficient, and recombining them to produce a final score) [102], and knowledge-based scoring 
functions (statistical analysis of solved ligand-protein complex structures) [103]. DOCK [104], 
AutoDock [105], and GOLD [106] use force-field-based scoring functions, LUDI [107] and 
PLANTSPLP [108] use empirical scoring functions, and SMoG2001 [109] uses knowledge-based 
scoring functions. 
Pharmacophore-based virtual screening methods find compounds that match a set of features 
with a certain spatial organization. It does not provide a ranking (in its simplest form) but rather a 
yes/no classification. The features are mapped from existing compounds (shared features) or directly 
set from the binding site. Pharmacophore modeling usually generates conformations on-the-fly. The 
control group should possess all the features used to screen the compounds. The screening 
performance is usually assessed from the ability of the pharmacophore to retrieve known ligands and 
decoys (true positives and negatives, false positives and negatives); a standard method is to use 
receiver operating characteristic curves [110]. 
An alternative approach, which overcomes the limitations of virtual libraries, is computational 
de novo design. This can produce unlimited innovation in generating novel small molecule ligands 
that bind protein targets. Based on initial constraints generated from the input, this method is divided 
into two strategies: ligand-based (if there is no structure available) and receptor-based [111]. We 
discuss only the latter. In the receptor-based strategy, the binding site on the target protein is 
identified and used to generate shape constraints for ligand docking and ligand-receptor interactions 
(hydrogen bond, electrostatic, and hydrophobic interactions). Methods that can be used to derive 
interaction sites include rule-based and grid-based methods [111]. The outcome of both is a map of 
the protein target displaying sites where a ligand might interact favorably. The other method, 
Multiple Copy Simultaneous Search (MCSS), can determine energetically favorable ligand positions 
and predict the orientations of the ligand functional groups in the binding site [112]. After 
randomized positioning of multi-copies of functional groups in the binding pocket, force field 
minimization is performed and the fragments with the interaction energy below a set threshold are 
chosen as starting fragments for filtering and further assembly. 
For ligand assembly within the binding site, single atoms or fragments can be used as the basic 
building blocks. The former approach generates more structural variety but increases the number of 
probable solutions, leads to longer processing times and so makes it more difficult to find suitable 
candidates. The fragment based-building block method is thus more common nowadays as it reduces 
the size of the search space significantly, making it faster to find solutions with chemically stable, 
easy-to-make, drug-like compounds. Further ligand assembly can be performed using e.g. the linking 
method or the growing method. In the linking method, the fragments are placed in key interaction 
sites of the binding site and then connected to each other using linkers to create complete molecules. 
The growing method starts with the placement of a single fragment at a key interaction site of the 
binding site. The fragment is then grown to introduce proper interactions between the ligand and 
both the key interaction sites and regions between key interaction sites in the binding site.  
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LigBuilder [113] and SPROUT [114] are two programs that use both methods for ligand assembly, 
the latter of which has been used for de novo ligand design to transmembrane regions of membrane-
bound proteins [115]. 
5.4. Hit expansion and lead optimisation 
Once initial hits have been identified by experimental or virtual screening (above), the library 
must be expanded (hit expansion). This can be done by building focused compound libraries, for 
example enriched in phosphate bioisosteres. As reviewed elsewhere [116,117], such compounds 
include phosphonates, carboxylates and malonates, sulfamates, squaramides and squaric acids, 
boron-containing fragments, and phosphorothioates. Hit expansion usually starts with the testing of 
analogues or compounds sharing similar properties. The binding site structure can be used to guide 
the synthesis from X-ray crystallography or from docking studies, i.e. structure-based compound 
design. The most promising compounds are then optimized through an extensive synthesis program, 
usually investigating the effect of bioiosteric replacement or changes in the main scaffold (scaffold 
hopping) combined with a battery of tests in vitro and in vivo. Current best practice includes ADME 
testing [91] as early as possible, as a “mistake” of the field has been a too early strong focus on 
potency [118]. Hit compounds will be a starting point, but they can also be used as chemical probes 
to verify the tractability of the target [119]. Chemical probes may also be critical for the development 
of cheaper or more robust screening assays. 
Two examples exemplify the possibilities for discovering inhibitors of the mPPases: FPPS and 
the deoxycytidine triphosphate pyrophosphatase 1 (dCTPase). FPPS is an important drug target that, 
like mPPase, binds bisphosphonates. Inhibitors of FPPS have been derived from natural ligands [120] 
and have been pursued from NMR screening of 400 fragments followed by X-ray  
crystallography [121]. Another approach for this enzyme used virtual screening of a small library of 
one thousand compounds followed by two rounds of analogue similarity search of the hits, 
identifying new classes of FPPS inhibitors, diterpenoids and sesquiterpenoids. This was followed by 
X-ray crystallography to show that these compounds bind to the isopentenyl diphosphate (IPP)  
site [122] or to a snapshot conformation found in molecular dynamics simulations [123]. Overall, 
these studies have identified that FPPS can be inhibited by binding at three different sites: the acid-
rich catalytic site involved in the binding of three Mg2+, the homoallylic site IPP site, a highly 
positively charged binding pocket and a modulatory site. dCTPase, which regulates the intracellular 
nucleotide pool through hydrolytic degradation of canonical and noncanonical nucleotide 
triphosphates (dNTPs), is highly expressed in many cancers. For dCTPase, a collection of 5,500 
compounds was screened using a classical high-throughput-adapted Malachite Green assay [124], a 
test for the colorimetric detection of inorganic phosphate and the hits optimized using a classical 
medicinal chemistry approach [125]. 
5.5. Tractability of the mPPase binding site 
The importance of mPPases, the availability of its structure and the fact that mammals do not 
contain homologous proteins make this enzyme a feasible target for drug design. Though the 
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structure of an mPPase from a pathogenic organism has not yet been solved, structure-based drug 
design against this group of enzymes is possible using the available solved structure from T. 
maritima and mung bean, since they have high sequence identity (40 - 43% and 44 - 53% between 
mPPases from pathogens P. falciparum, T. gondii, T. brucei, Leishmania mexicana, and B. vulgatus 
with TmPPase and VrPPase, respectively) with the highest sequence identity in the catalytic regions. 
Moreover, even though TmPPase and VrPPase translocate different ions and have 42% sequence 
identity, the active site of both structures are very similar with a root mean square deviation/Cα of 
0.84 Å (based on the structure of VrPPase:IDP:Mg5 and TmPPase:Pi2:Mg4), despite the fact that one 
is in the resting state and the other has inhibitor bound. This demonstrates the low flexibility of 
mPPase in the active site, even between different conformations and different species. mPPases from 
pathogens will also have a similar structure. 
Some PPase inhibitors, such as IDP and bisphosphonate derivatives, inhibit mPPase more than 
sPPases [6,69]. This is because, even though both sPPase and mPPase hydrolyze PPi, their active site 
and hydrolytic mechanism are completely different; it is therefore possible to develop drugs that 
specifically target mPPase but not sPPase. The structural differences and mechanisms of both 
enzymes were comprehensively explained in Kajander et al. [6]. 
The first step in designing drugs against mPPase is identifying ligand-binding sites. The most 
obvious is the catalytic pocket on the cytoplasmic side of the membrane: competitive inhibitors, like 
IDP and bisphosphonates, inhibit mPPase activity by competitively binding there, and so these 
molecules can be used as initial leads for finding other compounds with drug-like properties that 
specifically target mPPase. In the structure of VrPPase with inhibitor bound (VrPPase:IDP:Mg5) [12], 
IDP is bound in the acidic environment of a tunnel-like pocket, specifically to the side chain of 
residues K2505.58, D2535.61, D69115.61, K69415.64, D72716.35, K73016.38, and D73116.39. Upon IDP 
binding the overall hydrolytic pocket is constricted compared to the open conformation of the 
TmPPase in the resting state (Figure 2). Inhibition assays of VrPPase show that 
aminomethylenediphosphonate (AMDP) has a six times greater inhibitory effect on enzyme activity 
than IDP [126], but the opposite is true for the sPPase from S. cerevisiae (ScPPase) (53). Analysis of 
the ScPPase structures in the resting (pdb code: 1HUJ) and PPi bound states (pdb code: 1E6A) 
showed that the volume of the pocket is smaller than in mPPase [127]. The greater inhibition of 
mPPase by AMDP than IDP might be due to the larger pocket size, especially in the resting state 
structure. Therefore, in order to achieve better fitting and specificity for binding to the hydrolytic 
pocket of mPPase, de novo design by growing/linking methods can be employed based on the 
AMDP molecule. The initial hits identified from the structure-based design approaches described 
above could be further refined using a combination of compound synthesis and screening to increase 
on-target potency and selectivity against mPPase from human pathogens. The best inhibitor could 
also be co-crystallized with the mPPase for structure determination to analyze the binding mode of 
the inhibitor. Developing or identifying new compounds that bind selectively to the active site of 
mPPases and inhibit activity should lead to novel treatment options against several human pathogens. 
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6. Conclusion and Perspectives 
A major hurdle for drug discovery against human pathogens is ensuring minimal toxicity 
towards the host; even antimicrobials that have been approved for use in humans are continuously 
monitored for evidence of toxicity [128,129]. An important strategy to minimize the chance of 
harming human cells is to target biological components that are not present in animals. In this respect, 
since animals lack an mPPase gene, mPPases are a credible, novel target for drug design against 
human pathogens that express this enzyme, including several species of protozoan parasites and 
prokaryotic Bacteroides species. Of the mPPase-expressing human pathogens, malaria, which is 
caused by protozoan parasites, is arguably the most devastating globally, especially considering that 
78% of deaths due to malaria occur in children under the age of 5 [45]. 
mPPases play a critical role in stress tolerance and, in protozoa particularly, in adapting to 
osmotic stress. mPPases appear to be crucial for the various transitions in environment and protozoan 
cell type that occur over the complex parasitic life cycle. The solved structures of two mPPases, the 
H+-pumping, K+-dependent V. radiata mPPase and the Na+-pumping T. maritima mPPase, are a 
good basis for structure-based drug design, either to develop novel molecules or repurpose known 
molecules against mPPases. In addition to the static structural information gained through 
crystallographic means, complementary dynamics experiments and modeling can contribute to the 
drug-discovery process by providing further information regarding conformational changes during 
the catalytic cycle of the enzyme. 
However, additional mPPase structures, particularly of a protozoan H+-pumping mPPase and a 
Na+/H+ dual-pumping mPPase, as found in Bacteroides species, would provide valuable information 
for specifically targeting human pathogens that possess these types of enzymes. Although there are 
many questions still to be answered in the field, the current state of structural knowledge and the 
experiments underway in our and other laboratories around the world mean that mPPase is an 
intriguing candidate for developing precision drugs – ones with a unique target, and so with a 
reduced chance of side-effects. 
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